Neurophage Pharmaceuticals Awarded Second Grant for Parkinson’s Disease Program

Cambridge, MA-based Neurophage Pharmaceuticals has been awarded a second grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) for further development of its second generation drug candidate, NPT088. The drug is based on Neurophage’s general amyloid interaction motif (GAIM) technology, which can simultaneously target multiple misfolded proteins and reduce levels of pathogenic protein aggregates. In preclinical studies, treatment with GAIM-based candidates led to reduced levels of protein plaques and to cognitive behavioral improvements in animal models. The GAIM-based therapies holds promise for a broad range of neurodegenerative diseases associated with misfolded proteins, including ALS. We have previously reported on exciting developments in Neurophage’s pipeline in the June 3, 2013 Conference News Story. Neurophage will leverage the funding from MJFF to conduct preclinical studies on the effect of NPT088 on alpha-synuclein accumulation in the brain. In parallel, Neurophage has an active program in Alzheimer’s Disease, and is on track to begin clinical trials in 2015 for testing whether its drug candidate can successfully break down aggregates of amyloid beta or tau protein in humans.

Cambridge, MA-based Neurophage Pharmaceuticals has been awarded a second grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) for further development of its second generation drug candidate, NPT088. The drug is based on Neurophage’s general amyloid interaction motif (GAIM) technology, which can simultaneously target multiple misfolded proteins and reduce levels of pathogenic protein aggregates. In preclinical studies, treatment with GAIM-based candidates led to reduced levels of protein plaques and to cognitive behavioral improvements in animal models. The GAIM-based therapies holds promise for a broad range of neurodegenerative diseases associated with misfolded proteins, including ALS. We have previously reported on exciting developments in Neurophage’s pipeline in the June 3, 2013 Conference News Story. Neurophage will leverage the funding from MJFF to conduct preclinical studies on the effect of NPT088 on alpha-synuclein accumulation in the brain. In parallel, Neurophage has an active program in Alzheimer’s Disease, and is on track to begin clinical trials in 2015 for testing whether its drug candidate can successfully break down aggregates of amyloid beta or tau protein in humans.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail